Skip to main content
. 2016 Mar 31;114(8):855–862. doi: 10.1038/bjc.2016.30

Figure 3.

Figure 3

Combined VEGF/Ang-2 biomarker analysis. Forest plots of hazard ratios (bevacizumab plus chemotherapy vs placebo plus chemotherapy) for (A) progression-free survival by biomarker and (B) overall survival by biomarker (high VEGF/high Ang-2; high VEGF/low Ang-2; low VEGF/high Ang-2 and low VEGF/low Ang-2).